Search

Displaying results 2041 - 2050 of 10000 in total
  1. Drug

    Lenalidomide

    go.drugbank.com/drugs/DB00480
    ApprovedInvestigational

    [A228708] Available as oral capsules, lenalidomide is approved by the FDA and EU for the treatment of multiple myeloma, myelodysplastic syndromes, mantle cell lymphoma, follicular lymphoma, and marginal … contain an imide group.

  2. Drug

    Sodium tartrate

    go.drugbank.com/drugs/DB13707
    ApprovedWithdrawn

    Sodium tartrate is generally recognized as safe (GRAS) as a direct human food ingredient. It acts as an emulsifier and pH control agent in food products [L2590]. … Sodium tartrate is a disodium salt of l-( + )-tartaric acid that is identified by transparent, colorless, and odorless crystals. It is obtained as a byproduct of wine manufacturing.

    Categories: Drugs for ConstipationSynonyms: sodium L-tartrate, Disodium L-(+)-tartrate
  3. Drug

    Prezatide

    go.drugbank.com/drugs/DB11296
    Approved

    Prezatide is a tripeptide consisting of glycine, histidine, and lysine which readily forms a complex with copper ions [A19503]. Prezatide is used in cosmetic products for the skin and hair. … It is known to aid wound healing and its potential applications in chronic obstructive pulmonary disease and metastatic colon cancer are currently being investigated.

    Synonyms: Glycyl-L-histidyl-L-lysine
  4. Drug

    Daprodustat

    go.drugbank.com/drugs/DB11682
    ApprovedInvestigational

    [A254172] In June 2020, daprodustat was first approved in Japan for the treatment of renal anemia. … [L43857] On February 1, 2023, daprodustat was fully approved by the FDA as the first oral treatment for anemia caused by chronic kidney disease in patients on dialysis.

    Synonyms: Glycine, N-((1,3-dicyclohexylhexahydro-2,4,6-trioxo-5-pyrimidinyl)carbonyl)-
  5. Drug

    Anagrelide

    go.drugbank.com/drugs/DB00261
    ApprovedInvestigational

    [L14153] It is an oral imidazoquinazoline that was first approved for use in the US in 1997.[A214274] It appears to carry a better response rate than other thrombocythemia treatments (e.g. … Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms.

    Categories: Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexProducts: ANAGRELID AL 0.5MG HKP
  6. Drug

    Sodium oxybate

    go.drugbank.com/drugs/DB09072
    ApprovedInvestigational

    [A18723] For safety reasons, sodium oxybate is a controlled substance only available through a restricted program in approved countries. … [A251430] Due to its physiological effects, sodium oxybate is associated with a risk for substance misuse and abuse.

  7. Drug

    Tecovirimat

    go.drugbank.com/drugs/DB12020
    ApprovedInvestigational

    However, there have been longstanding concerns that smallpox may be used as a bioweapon.[A35133,L3614] Tecovirimat is an antiviral drug that was identified via a high-throughput screen in 2002. … The World Health Organization declared smallpox, a contagious and sometimes fatal infectious disease, eradicated in 1980.

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  8. Drug

    Methylphenobarbital

    go.drugbank.com/drugs/DB00849
    Approved

    A barbiturate that is metabolized to phenobarbital. It has been used for similar purposes, especially in epilepsy, but there is no evidence mephobarbital offers any advantage over phenobarbital.

    Synonyms: N-Methylphenobarbital
  9. Drug

    Bimekizumab

    go.drugbank.com/drugs/DB12917
    ApprovedInvestigational

    Bimekizumab is a humanized monoclonal antibody directed towards IL-17, which was approved for use in the EU on August 20, 2021, for the treatment of plaque psoriasis. … [A244455] It has demonstrated superior efficacy as compared to another IL-17 inhibitor, [secukinumab], as well as [ustekinumab] (an IL-12/23 inhibitor) and [adalimumab] (a TNF inhibitor) in the treatment

  10. Drug

    Rilzabrutinib

    go.drugbank.com/drugs/DB17709
    ApprovedInvestigational

    Rilzabrutinib is an oral, reversible, covalent inhibitor of Bruton's tyrosine kinase [A259078, L53738] that was approved by the FDA on August 29, 2025, for the treatment of persistent and chronic immune … [L53743] ITP is an autoimmune disorder characterized by low platelet count.

    Synonyms: (e/z)-(r)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)piperidine-1-carbonyl)-4-methyl-4-(4-(oxetan-3-yl)piperazin-1-yl)pent-2-enenitrile